Research desk / Research profile / EHC
Inside the research
Encompass Health Corporation EHC Research profile · latest available data
Price overview The Verdict Risk Metrics Material Events Insider Trades Top Holders
Buy
Our score +0.64
Short +0.78 Medium +0.62 Long +0.42
computed 2026-09-27
Encompass Health Corporation
Healthcare · Medical Care Facilities
Market cap $12.18B Enterprise value $15.78B Trailing P/E 20.61x Forward P/E 18.49x EV / EBITDA 10.78x P / S (ttm) 1.96x Profit margin 10.0% Return on equity 25.0% Revenue growth +9.6% Earnings growth +10.8% Debt / equity 82.12
Layer Raw Contribution Fundamental +0.27 Sector +0.08 Technical +0.16 Earnings +0.00 Sentiment +0.69
macro × 1.00 · 2026-09-27
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence, and quality of life; medical, nursing, therapy, and ancillary services; and rehabilitative care to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. It offers services through the Medicare program to the federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was incorporated in 1984 and is based in Birmingham, Alabama.
United States · www.encompasshealth.com
Beta vs SPX 0.39 Corr SPX 0.23 Annual vol 27.7% Annual ret +18.1% Sharpe 0.66 Max DD -26.2%
Window: 504 trading days (504 obs)
Mean PT $140.64 High / Low $150.00 / $130.00 Median $140.00 Analysts 11
Strong Buy 1 Buy 11 Hold 0 Sell 0 Strong Sell 0
Recent rating actions
2026-05-05 Barclays → Overweight 2026-02-06 Barclays → Overweight 2025-10-30 Barclays → Overweight 2025-10-02 UBS → Buy 2025-09-16 Keybanc → Overweight 2025-09-10 B of A Securities → Buy
Date Event 8-K 2026-08-13 Other Material Event read 2026-08-05 Earnings Release, Reg FD Disclosure… read 2026-06-01 Material Agreement, Material Obligation… read 2026-05-15 Material Agreement, Other Material Event… read 2026-05-11 Shareholder Vote read 2026-04-30 Earnings Release, Reg FD Disclosure… read 2026-03-10 Material Agreement, Termination of Agreement… read 2026-02-05 Earnings Release, Reg FD Disclosure… read 2026-02-02 Officer / Director Change, Exhibits read 2025-12-01 Reg FD Disclosure read 2025-10-29 Earnings Release, Reg FD Disclosure… read 2025-09-18 Officer / Director Change read
Date Insider Role Action Shares Value 2026-08-10 Darby John Patrick EVP, Gen Counsel & Secret Sell 8.91K $1.12M 2026-08-10 Tarr Mark J President & CEO Sell 171.57K $21.53M 2026-08-10 Tarr Mark J President & CEO Sell 1.58K $199.05K 2026-08-10 COLTHARP DOUGLAS E EVP & Chief Financial Off Sell 18.87K $2.37M 2026-07-16 Christie Edward M III Grant 248 $27.88K 2026-07-16 Reidy Christopher R Grant 319 $35.86K 2026-07-15 KATZ LESLYE G Grant 85 — 2026-07-15 HERMAN JOAN E Grant 85 — 2026-07-15 Reidy Christopher R Grant 21 — 2026-07-15 Christie Edward M III Grant 11 —
Insider 180d net -$25.21M Insider buys / sells 0 / 4 Insider bias Sellers 13F holders 9 Top-5 share 95.2% HHI 2,960 (concentrated)
Holder Value Shares State Street Corp $322.02M 3.19M Citadel Advisors $265.21M 2.62M Millennium Management $81.44M 805.72K AQR Capital Management $56.58M 561.89K Capital Research / Capital World $27.96M 276.61K Renaissance Technologies $17.64M 174.50K Fidelity / FMR LLC $15.44M 152.78K Bridgewater Associates $4.15M 41.02K T. Rowe Price Group $511.04K 5.06M
As of 2026-06-30
Yield (TTM) 0.46% $ / share (TTM) $0.57 5y CAGR -4.7%
Annual dividend per share
2021 $0.89 2022 $0.80 2023 $0.60 2024 $0.47 2025 $0.70 2026 $0.38
FY 2010–2025 · 16 years
Line Latest CAGR Trend Revenue $4.80B +24.3% Operating income $539.50M +29.1% Net income $566.20M +12.7% Cash from ops $715.80M +6.6%
Date Open High Low Close Vol Sep 25 $121.81 $124.51 $121.72 $123.47 1.22M Sep 24 $122.86 $124.54 $121.37 $122.01 849.60K Sep 23 $122.73 $124.84 $121.91 $122.21 954.40K Sep 22 $122.06 $125.08 $119.48 $122.76 1.14M Sep 21 $121.74 $123.67 $120.07 $121.56 801.50K
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →